Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMAPP: Single vs Multiple-dose Antibiotics for POEM
NCT03784365Phase 3Unknown
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefoperazone + sulbactam in bacterial infection (2 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Infectious complications associated with POEM at 1 month. Status: unknown.
02
Drugs
cefoperazone + sulbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03784365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784365.